Quick Update for Zimmer Biomet (ZBH) Investors

By Tamara Parker • Wednesday, April 16 09:59 • Permanent Link

One of the losers of today's trading session was Zimmer Biomet. Shares of the Specialty industrial machinery company plunged -4.6%, and some investors may be wondering if its price of $97.27 would make a good entry point. Here's what you should know if you are considering this investment:

Zimmer Biomet has moved -19.8% over the last year, and the S&P 500 logged a change of 7.5%
ZBH has an average analyst rating of hold and is -20.5% away from its mean target price of $122.35 per share
Its trailing earnings per share (EPS) is $4.43
Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 22.0 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $8.6 and its forward P/E ratio is 11.3
The company has a Price to Book (P/B) ratio of 1.55 in contrast to the S&P 500's average ratio of 4.74
Zimmer Biomet is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
ZBH has reported YOY quarterly earnings growth of -40.5% and gross profit margins of 0.7%
The company has a free cash flow of $1.06 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.